| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/28/2007 | CN1919874A Antibody molecule ATF-Fc fusion albumen of antiurokinase type fibrinolysin activator receptor and use thereof |
| 02/28/2007 | CN1919873A Fusion albumen containing HSP70 ATPase structure field and mammal p53 albumen and application thereof |
| 02/28/2007 | CN1919872A Fusion albumen containing HSP70 ATPase structure field and antigen peptide and application thereof |
| 02/28/2007 | CN1919870A Cat alpha interferon, encode gene and application thereof |
| 02/28/2007 | CN1919868A Chronic neuralgia related albumen and gene thereof |
| 02/28/2007 | CN1919865A Bioactivity peptide, preparing process and application thereof |
| 02/28/2007 | CN1919342A Canine tumor treatment method, pharmaceutical formulation applied thereto, and method of cryogenically preserving cells used therewith |
| 02/28/2007 | CN1919339A Cucurbitacin nano preparation comprising protein, preparation method and use thereof |
| 02/28/2007 | CN1919338A Insulin liquid formulations for nose administration |
| 02/28/2007 | CN1919337A Insulin powder nose inhalant and preparing process thereof |
| 02/28/2007 | CN1919336A Method for preparing high activity long-acting PEG-interferon position isomer hybrid medicine |
| 02/28/2007 | CN1919335A Albumen powder capsule |
| 02/28/2007 | CN1919179A Anticancer slow release preparation of nimustine and its progression agent |
| 02/28/2007 | CN1919160A Nano antibiotic antiviral condom |
| 02/28/2007 | CN1302115C Buffer solution for electroporation and a method comprising the use of the same |
| 02/28/2007 | CN1302113C Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
| 02/28/2007 | CN1302109C Horny cell growth factor mutant and its preparation method and use thereof |
| 02/28/2007 | CN1302107C Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth |
| 02/28/2007 | CN1302103C CD 19XCD3 specific polypeptides and uses thereof |
| 02/28/2007 | CN1302010C Disulfide cross-linked glycoprotein hormone analogs, their preparation and use |
| 02/28/2007 | CN1301994C Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 02/28/2007 | CN1301747C Protein medicine microcapsule and inhalational aerosol thereof |
| 02/28/2007 | CN1301723C Method for purifying and preparing anti-tumor factor-cathepsin beta inhibiting factor from soybean or bean dregs |
| 02/28/2007 | CA2557246A1 Nk3 receptor in vivo assay |
| 02/28/2007 | CA2538408A1 Diet product, oral drug and method for treating allergies using tgf-.beta.1 |
| 02/27/2007 | USRE39497 Storage of materials |
| 02/27/2007 | USRE39496 Kahalalide F and compositions and uses thereof |
| 02/27/2007 | US7183430 Compounds which can block the response to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, production method thereof and compositions containing same |
| 02/27/2007 | US7183416 Polymorph of a pharmaceutical |
| 02/27/2007 | US7183402 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 02/27/2007 | US7183401 Tumor suppressor protein (designated NOEY2) expressed in normal ovarian and breast surface epithelial cells but absent or down-regulated in ovarian and breast cancer cells; vectors, host cells, detection kits |
| 02/27/2007 | US7183400 Use of ULIP proteins in the diagnosis and therapy of cancers and paraneoplastic neurological syndromes |
| 02/27/2007 | US7183396 Linvin, a novel inhibitor of apoptosis protein |
| 02/27/2007 | US7183393 Fusion protein of a polypeptide and a heparan sulphate glycosaminoglycan chain which influences binding affinity, binding specificity, and stability; polypeptide of fusion protein can be a cell growth factor, pathogen-related antigen, nuclear protein, cell adhesion molecules, enzyme or enzyme inhibitor |
| 02/27/2007 | US7183391 Kunitz domain polypeptide zkun10 |
| 02/27/2007 | US7183383 Uses of collagen IV |
| 02/27/2007 | US7183382 Mammalian genes; related reagents and methods |
| 02/27/2007 | US7183380 Use in diagnosing and treating neurological conditions and in identification of compounds that alter IMX97018 polypeptide activities |
| 02/27/2007 | US7183379 Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1 |
| 02/27/2007 | US7183376 Variant B7 co-stimulatory molecules |
| 02/27/2007 | US7183375 Invention relates to peptide sequence which inhibits cleavage of calcineurin subunit A by calpain; cell death suppressant targeting the mechanism of the long term activation of calcineurin but not the calcineurin activation through the transient increase of the intracellular concentration of calcium |
| 02/27/2007 | US7183374 Diminishing concentration of metal complex from solution containing the complex by addition of an optionally fused and/or optionally substituted heterocyclic compound which is a solubility-enhancing compound that enhances solubility of complex in second solution |
| 02/27/2007 | US7183373 MNTF peptides and compositions and methods of use |
| 02/27/2007 | US7183302 Iminothiazolidinones as inhibitors of HCV replication |
| 02/27/2007 | US7183279 Synergistic combinations with morphine; analgesics and cyclooxygenase-2 inhibitors, such as N-5-guanidinopentanamide-(2S)-yl-2-N-(p-hydroxyphenylacetyl)phenylenediamine and N-5-guanidinopentanamide-(2R)-yl-2-N-(p-hydroxybenzyl)-5-carboxybenzimidazole |
| 02/27/2007 | US7183262 Administering a construct of a polynucleotide linked to a heat-inducible promoter encoding a therapeutic polypeptide at a site at or near the tumor; and applying heat to the site at or near the tumor to express the polypeptide |
| 02/27/2007 | US7183260 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 02/27/2007 | US7183259 Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
| 02/27/2007 | US7183258 Cytolytic agents; side effect reduction |
| 02/27/2007 | US7183257 Use of RPL41 to treat infections and inhibit cancer |
| 02/27/2007 | US7183256 Polypeptide comprising a portion of carboxy terminal of tissue inhibitor of metalloprotease (TIMP) for use as an inhibitor of endothelial growth factor (VEGF) activities and angiogenesis; treatment and preventative of cell proliferative disorders |
| 02/27/2007 | US7183255 Administering vasopressin receptor agonist such as arginine vasopressin to subject, thereby maintaining blood pressure during hemodialysis in order to facilitate reducing excess extracellular fluid in subject |
| 02/27/2007 | US7183254 Diagnosis, hormone replacement therapy for HIV positive females, gene therapy; metabolic disorders; antidiabetic, anticholesterol, hypoglycemic agents |
| 02/27/2007 | US7183253 Substantially pure glycopeptide antibiotics AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 |
| 02/27/2007 | US7183252 Treatment of restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, angiogenesis related disorders, cancer, and neurodegenerative disorders. |
| 02/27/2007 | US7183251 hCG therapy for the treatment of breast cancer |
| 02/27/2007 | US7183101 NCC2705—the genome of a bifidobacterium |
| 02/27/2007 | US7183100 Mitigating virulence of mucoid bacteria via exposure to enzyme inhibitors; bactericides and controlling propagation of exopolysaccharide biofilms |
| 02/27/2007 | US7183095 Cell culture system for synthesis of infectious hepatitis C virus |
| 02/27/2007 | US7183082 in vitro and in vivo; involves incorporating an unnatural amino acid into a protein and attaching one or more saccharide moieties to the unnatural amino acid; mimetics |
| 02/27/2007 | US7183081 Nucleotide sequences coding cytokine polypeptide for use in identifying modulator for treatment or arthritis, allergies, infections, inflammation, skin and cell proliferative disorders; wound healing agents |
| 02/27/2007 | US7183080 Cannie IL-5 nucleic acid molecules |
| 02/27/2007 | US7183075 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 02/27/2007 | US7183070 Using reduction in beta site amyloid precursor protein cleaving enzyme activity, manifested as decreased beta amyloid peptides production, as diagnostic indicator of enzyme inhibition; for use in treatment of amyloid deposition disorders |
| 02/27/2007 | US7183065 Diagnosing ulcerative colitis in humans; obtain sample tissue, incubate with histone antigen, detect presence of complex formation, presence of complex indicates ulcerative colitis |
| 02/27/2007 | US7183063 Can be used in screening for agents which act as antagonists to MCP-1, MIP-1 alpha and/or RANTES |
| 02/27/2007 | US7183054 Glyceraldehyde-3-phosphate dehydrogenase and Saframycin A/dna complexes; evaluation of microbiocidal and antiproliferative activity |
| 02/27/2007 | US7183051 Diagnosis and treatment of cancer |
| 02/27/2007 | US7183046 Human polypeptide for use as an antitumor agent |
| 02/27/2007 | US7182962 Swine plasma albumin; gene expression of immunostimulant; prevent infections; anticancer agents |
| 02/27/2007 | US7182956 Entrapping in phosphatidylcholine component; room temperature transdermal delivery system; long shelf life |
| 02/27/2007 | US7182949 Composition comprising vitamin C prepared during application, use of enzymes for forming vitamin C for topical use, and a cosmetic treatment method |
| 02/27/2007 | US7182945 End group acylation; genetic engineering; rheumatic diseases, respiratory system disorders |
| 02/27/2007 | US7182942 Vaccine immunotherapy for immune suppressed patients |
| 02/27/2007 | CA2256410C Stable pharmaceutical composition of bdnf |
| 02/23/2007 | CA2513027A1 Method of inhibiting vascular permeability |
| 02/22/2007 | WO2007022537A2 Use of lactoferrin as a chemokine and a chemotactic modulator |
| 02/22/2007 | WO2007022534A1 Preparation of a peptide compound (norapro-2002) and its use for the activation of protein phosphatase-2a enzymes |
| 02/22/2007 | WO2007022515A2 Stem cell derived factors for treating pathologic conditions |
| 02/22/2007 | WO2007022287A2 Modified vegf and pdgf with improved angiogenic properties |
| 02/22/2007 | WO2007022255A2 Pharmaceutical formulations for sustained release |
| 02/22/2007 | WO2007022140A2 Methods of improving cardiac function and attenuating and/or preventing cardiac remodeling with hsp20 |
| 02/22/2007 | WO2007021900A2 Compositions and methods for treating wounds |
| 02/22/2007 | WO2007021822A2 Compositions and methods of preparation of liposomal microparticulate il-12 |
| 02/22/2007 | WO2007021807A1 Mcp1 fusions |
| 02/22/2007 | WO2007021572A2 Use of peptides that bind to tpo receptor |
| 02/22/2007 | WO2007021498A1 Selective vpac2 receptor peptide agonists |
| 02/22/2007 | WO2007021253A1 Compounds and methods for inhibiting hepatitis c virus replication |
| 02/22/2007 | WO2007020935A1 Therapeutic agent for pain comprising p2y12 receptor and/or p2y14 receptor blocker |
| 02/22/2007 | WO2007020922A1 Remedy and preventive for cerebral diseases |
| 02/22/2007 | WO2007020889A1 Novel mucin glycoprotein and use thereof |
| 02/22/2007 | WO2007020871A1 Technique for stabilization of yw753 reparation |
| 02/22/2007 | WO2007020672A2 Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease |
| 02/22/2007 | WO2007020405A2 Integrin i-domain binding peptides |
| 02/22/2007 | WO2007020403A1 Azapeptides for treating hyperalgesic pain conditions |
| 02/22/2007 | WO2007020402A1 Insulin-like growth factor ii (igf-ii) binding factors |
| 02/22/2007 | WO2007020386A2 Apoe mimetic agents |
| 02/22/2007 | WO2007020260A2 Pancreatin micropellet cores suitable for enteric coating |
| 02/22/2007 | WO2007020259A2 Controlled release pharmaceutical compositions for acid labile drugs |
| 02/22/2007 | WO2007020195A2 Peg-ifn alpha and ribavirin for hbv treatment |